It is of interest to note that, despite the improved anti-AML activity of CD123-CAR-IL15-T cells, leukemia eventually progressed in PDX-AML models; this late therapeutic failure seemed to be due to a decreased CD123 expression post CD123 CAR-T cell therapy [123]. This evidence concerns the gene IL15 and acute myeloid leukemia.